Cancer Focused Clovis Oncology Files For Bankruptcy
Cancer Focused Clovis Oncology Files For Bankruptcy
癌症集中克洛維斯腫瘤科文件破產
- Clovis Oncology Inc (NASDAQ:CLVS) has voluntarily initiated a Chapter 11 proceeding in the U.S. Bankruptcy Court and will seek to sell its assets through a court-supervised sales process.
- The Debtors have filed various "first day" motions with the Bankruptcy Court requesting customary relief that will enable them to transition into Chapter 11 without material disruption to their ordinary course operations.
- Related: Clovis Oncology Shares Nose-Dive As Potential Bankruptcy Filing Looms.
- Clovis has received a commitment of up to $75 million in a multi-draw debtor-in-possession (DIP) financing facility.
- Before the Chapter 11 filing, and subject to Bankruptcy Court approval, Clovis entered into a "stalking horse" purchase and assignment agreement with Novartis Innovative Therapies AG for FAP-2286 for an upfront payment of $50 million and up to an additional $333.75 million as development & regulatory milestones and $297 million in later sales milestones.
- Clovis is also actively engaged in discussions with several interested parties for a potential sale of one or more of its other assets.
- Price Action: CLVS shares are down 11.50% at $0.18 during the premarket session on the last check Monday.
- 克洛維斯腫瘤科 NASDAQ：CLVS）已在美國破產法院自願發起了第 11 章程序，並將尋求通過法院監督的銷售流程出售其資產。
- 債務人已向破產法院提交了各種「第一天」議案，要求慣常救濟，這將使他們能夠過渡到第 11 章，而不會對其普通課程運作造成重大干擾。
- 相關： 克洛維斯腫瘤學股票鼻子潛水作為潛在的破產申請織機。
- Clovis 在一個多平局擁有債務人（DIP）融資機構中獲得了高達 7500 萬美元的承諾。
- 在第 11 章提交申請之前，克洛維斯與諾華創新療法股份公司簽訂了「纏擾馬」購買和分配協議，用於 FAP-2286 的前期付款 5,000 萬美元，額外支付 333.75 億美元的發展和監管里程碑，以及 2.97 億美元的後續銷售里程碑。
- Clovis 還積極與幾個有興趣方進行討論，以便潛在出售其一個或多個其他資產。
- 價格行動： CLVS 股票在上次檢查週一的盤前時段下跌了 11.50%，為 0.18 美元。
資訊熱榜
更新時間